Literature DB >> 34022451

Distinct Clinical Physiologic Phenotypes of Patients With Laryngeal Symptoms Referred for Reflux Evaluation.

Rena Yadlapati1, Alexander M Kaizer2, Daniel R Sikavi3, Madeline Greytak4, Jennifer X Cai3, Thomas L Carroll5, Samir Gupta4, Sachin Wani6, Paul Menard-Katcher6, Tsung-Chin Wu7, Philip Weissbrod8, Andrew M Vahabzadeh-Hagh8, John E Pandolfino9, Walter W Chan3.   

Abstract

BACKGROUND & AIMS: Heterogeneous presentations and disease mechanisms among patients with laryngeal symptoms account for misdiagnosis of laryngopharyngeal reflux (LPR), variations in testing, and suboptimal outcomes. We aimed to derive phenotypes of patients with laryngeal symptoms based on clinical and physiologic data and to compare characteristics across phenotypes.
METHODS: A total of 302 adult patients with chronic laryngeal symptoms were prospectively enrolled at 3 centers between January 2018 to October 2020 (age 57.2 ± 15.2 years; 30% male; body mass index 27.2 ± 6.0 kg/m2). Discriminant analysis of principal components (DAPC) was applied to 12 clinical and 11 physiologic variables collected in stable condition to derive phenotypic groups.
RESULTS: DAPC identified 5 groups, with significant differences across symptoms, hiatal hernia size, and number of reflux events (P < .01). Group A had the greatest hiatal hernia size (3.1 ± 1.0 cm; P < .001) and reflux events (37.5 ± 51; P < .001), with frequent cough, laryngeal symptoms, heartburn, and regurgitation. Group B had the highest body mass index (28.2 ± 4.6 kg/m2; P < .001) and salivary pepsin (150 ± 157 ng/mL; P = .03), with frequent cough, laryngeal symptoms, globus, heartburn, and regurgitation. Group C frequently reported laryngeal symptoms (93%; P < .001), and had fewest esophageal symptoms (9.6%; P < .001) and reflux events (10.7 ± 11.0; P < .001). Group D commonly reported cough (88%; P < .001) and heartburn. Group E (18%) was oldest (62.9 ± 14.3 years; P < .001) and distinguished by highest integrated relaxation pressure.
CONCLUSIONS: DAPC identified distinct clinicophysiologic phenotypes of patients with laryngeal symptoms referred for reflux evaluation: group A, LPR and gastroesophageal reflux disease (GERD) with hiatal hernia; group B, mild LPR/GERD; group C, no LPR/No GERD; group D, reflex cough; and group E, mixed/possible obstructive esophagogastric junction. Phenotypic differences may inform targeted clinical trials design and improve outcomes.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Esophageal Manometry; Gastroesophageal Reflux Disease; Proton Pump Inhibitor

Mesh:

Year:  2021        PMID: 34022451      PMCID: PMC8715518          DOI: 10.1016/j.cgh.2021.05.025

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  22 in total

1.  Proton Pump Inhibitor Therapy for the Treatment of Laryngopharyngeal Reflux: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Huaiyuan Guo; Haijun Ma; Jinliang Wang
Journal:  J Clin Gastroenterol       Date:  2016-04       Impact factor: 3.062

2.  Changing impact of gastroesophageal reflux in medical and otolaryngology practice.

Authors:  Kenneth W Altman; Robbin M Stephens; Christopher S Lyttle; Kevin B Weiss
Journal:  Laryngoscope       Date:  2005-07       Impact factor: 3.325

3.  Identification of Different Phenotypes of Esophageal Reflux Hypersensitivity and Implications for Treatment.

Authors:  Akinari Sawada; Mauricio Guzman; Kornilia Nikaki; Shirley Sonmez; Etsuro Yazaki; Qasim Aziz; Philip Woodland; Benjamin Rogers; C Prakash Gyawali; Daniel Sifrim
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-06       Impact factor: 11.382

4.  The role of the vague nerve in airway narrowing caused by intraesophageal hydrochloric acid provocation and esophageal distention.

Authors:  L E Mansfield; H H Hameister; H S Spaulding; N J Smith; N Glab
Journal:  Ann Allergy       Date:  1981-12

5.  Symptom overlap between laryngopharyngeal reflux and glottic insufficiency in vocal fold atrophy patients.

Authors:  Anju K Patel; Nicholas R Mildenhall; William Kim; Thomas L Carroll
Journal:  Ann Otol Rhinol Laryngol       Date:  2014-04       Impact factor: 1.547

6.  Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.

Authors:  Anders Mälarstig; Daniel Ziemek; Lars Lund; Åsa K Hedman; Camilla Hage; Anil Sharma; Mary Julia Brosnan; Leonard Buckbinder; Li-Ming Gan; Sanjiv J Shah; Cecilia M Linde; Erwan Donal; Jean-Claude Daubert
Journal:  Heart       Date:  2020-01-07       Impact factor: 5.994

7.  Gastroesophageal reflux-induced bronchoconstriction. An intraesophageal acid infusion study using state-of-the-art technology.

Authors:  C A Schan; S M Harding; J M Haile; L A Bradley; J E Richter
Journal:  Chest       Date:  1994-09       Impact factor: 9.410

8.  Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care.

Authors:  R Jones; O Junghard; J Dent; N Vakil; K Halling; B Wernersson; T Lind
Journal:  Aliment Pharmacol Ther       Date:  2009-09-08       Impact factor: 8.171

9.  The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux.

Authors:  Julian A McGlashan; Lesley M Johnstone; John Sykes; Vicki Strugala; Peter W Dettmar
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-05-28       Impact factor: 2.503

10.  Pepsin in saliva for the diagnosis of gastro-oesophageal reflux disease.

Authors:  Jamal O Hayat; Shirley Gabieta-Somnez; Etsuro Yazaki; Jin-Yong Kang; Andrew Woodcock; Peter Dettmar; Jerry Mabary; Charles H Knowles; Daniel Sifrim
Journal:  Gut       Date:  2014-05-07       Impact factor: 23.059

View more
  2 in total

Review 1.  An update on current treatment strategies for laryngopharyngeal reflux symptoms.

Authors:  Amanda J Krause; Erin H Walsh; Philip A Weissbrod; Tiffany H Taft; Rena Yadlapati
Journal:  Ann N Y Acad Sci       Date:  2021-12-17       Impact factor: 6.499

2.  The Effect of Hyaluronic Acid and Chondroitin Sulphate-Based Medical Device Combined with Acid Suppression in the Treatment of Atypical Symptoms in Gastroesophageal Reflux Disease.

Authors:  Gaia Pellegatta; Benedetto Mangiavillano; Rossella Semeraro; Francesco Auriemma; Elisa Carlani; Alessandro Fugazza; Edoardo Vespa; Alessandro Repici
Journal:  J Clin Med       Date:  2022-03-29       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.